LDN-27219 CANCER TREATMENT RESEARCH - AN OVERVIEW

One significantly attention-grabbing compound is LDN-27219. When most tTG inhibitors are intended to bind for the protein crosslinking Energetic website, LDN-27219 rather binds into the nucleotide binding pocket with the enzyme although it is in its shut-condition conformation, and stabilizes that conformation to prevent crosslinking activity.seven